ClinicalTrials.Veeva

Menu
N

Northridge Clinical Trials | Northridge, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
TAK-279
Amlitelimab
Lorundrostat
Tirzepatide
Ixekizumab
PF-07264660
PF-07275315

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 12 total trials

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to...

Active, not recruiting
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2
Locations recently updated

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for athero...

Enrolling
Diabetes Mellitus, Type 2
Metabolic Syndrome
Device: The Cleerly CAD Staging System

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: TAK-279
Drug: Placebo
Locations recently updated

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling
Plaque Psoriasis
Drug: TAK-279
Locations recently updated

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Amlitelimab
Drug: Placebo

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Enrolling
Non-segmental Vitiligo
Drug: Vehicle Gel
Drug: VYN201 Gel

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315
Locations recently updated

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the pre...

Enrolling
Psoriasis
Obesity
Drug: Tirzepatide
Drug: Ixekizumab
Locations recently updated

This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypert...

Invitation-only
Hypertension
Drug: lorundrostat
Drug: Placebo

Trial sponsors

Amgen logo
M
Sanofi logo
Takeda logo
C
Lilly logo
Pfizer logo
Vyne Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems